LTR Pharma Ltd (ASX: LTP) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

LTR Pharma Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $89.05 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 181.73 million
Earnings per share -0.033
Dividend per share N/A
Year To Date Return -31.94%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • LTR Pharma Ltd (ASX: LTP)
    Latest News

    No posts found.

    LTP ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About LTR Pharma Ltd

    LTR Pharma Ltd. operates as a clinical-stage biopharmaceutical company. It focuses on improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. The company was founded by Rodne Eric Lee in October 2020 and is headquartered in Brisbane, Australia.

    LTP Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    06 Feb 2026 $0.49 $-0.02 -3.92% 416,688 $0.51 $0.51 $0.46
    05 Feb 2026 $0.51 $0.01 1.98% 192,543 $0.51 $0.51 $0.50
    04 Feb 2026 $0.51 $-0.03 -5.66% 147,319 $0.53 $0.54 $0.51
    03 Feb 2026 $0.53 $0.02 3.92% 116,099 $0.54 $0.54 $0.52
    02 Feb 2026 $0.51 $-0.04 -7.34% 203,537 $0.54 $0.54 $0.51
    30 Jan 2026 $0.55 $0.01 1.87% 399,595 $0.54 $0.55 $0.50
    29 Jan 2026 $0.54 $-0.02 -3.64% 251,772 $0.56 $0.56 $0.53
    28 Jan 2026 $0.55 $-0.03 -5.13% 196,116 $0.56 $0.57 $0.55
    27 Jan 2026 $0.59 $0.02 3.51% 261,748 $0.57 $0.59 $0.54
    23 Jan 2026 $0.57 $0.00 0.00% 240,613 $0.59 $0.59 $0.56
    22 Jan 2026 $0.57 $0.00 0.00% 540,220 $0.60 $0.63 $0.57
    21 Jan 2026 $0.57 $0.01 1.80% 110,471 $0.55 $0.57 $0.54
    20 Jan 2026 $0.56 $-0.01 -1.77% 286,629 $0.58 $0.58 $0.55
    19 Jan 2026 $0.57 $-0.01 -1.74% 376,234 $0.58 $0.58 $0.55
    16 Jan 2026 $0.58 $-0.01 -1.71% 154,132 $0.59 $0.60 $0.58
    15 Jan 2026 $0.59 $-0.01 -1.68% 187,821 $0.59 $0.62 $0.58
    14 Jan 2026 $0.60 $-0.02 -3.25% 604,299 $0.61 $0.62 $0.58
    13 Jan 2026 $0.62 $-0.03 -4.69% 127,738 $0.64 $0.64 $0.61
    12 Jan 2026 $0.64 $0.01 1.59% 119,786 $0.62 $0.64 $0.62
    09 Jan 2026 $0.63 $-0.02 -3.10% 130,015 $0.66 $0.66 $0.61

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    19 Nov 2025 Julian Chick Issued 1,000,000 $450,000
    Issue of options.
    19 Nov 2025 Lee Rodne Issued 2,000,000 $900,000
    Issue of options.
    19 Nov 2025 Maja McGuire Issued 1,000,000 $450,000
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Julian John Chick Non-Executive Director Nov 2020
    Dr Chick is an experienced healthcare executive with over 20 years of experience in senior management and board positions. He has eight years of investment banking experience and has also held a role as an analyst reviewing healthcare and biotechnology investment opportunities for private equity investors and venture capitalists.
    Mr Lee Rodne Executive ChairmanExecutive Director Oct 2020
    Mr Rodne holds over 25 years of experience in the healthcare and technology sectors and has been in executive leadership roles in both Public and Private enterprises. He was also the Senior Executive of Sirius Minerals Plc that led to its lead acquisition project and reached a peak market capitalisation of over $1 billion on the London Exchange.
    Ms Maja Aleksandra McGuire Non-Executive Director Sep 2021
    Ms McGuire is a corporate executive and company director, bringing over 15 years of experience at board and senior management level. This includes working with listed companies as a non executive chair/director, general counsel and in top tier legal private practice. She has led strategy and corporate development for both small startups focussed on growth and funding, and for larger mature organisations focussed on corporate transformation and investing in next generation assets and technology. She commenced her career at Clayton Utz, gaining experience in a broad range of corporate, commercial and banking matters. At Canadian Bankers Association, she advocated on issues pertaining to developments in domestic and international banking regulation. She is Chair of the Risk Committee.
    Mr Euh(David) Hwang Joint Company Secretary Apr 2025
    -
    Ms Elizabeth Spooner Joint Company Secretary Apr 2025
    -
    Euh(David) Hwang Joint Company Secretary
    -
    Elizabeth Spooner Joint Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Ltr Medical Pty Ltd 46,373,750 25.62%
    Strategic Drug Solutions Inc 5,933,000 3.28%
    Trexapharm Inc 4,188,000 2.31%
    Ubs Nominees Pty Ltd 3,085,377 1.70%
    Citicorp Nominees Pty Limited 3,058,439 1.69%
    Go Medical Industries Pty Ltd 2,443,000 1.35%
    Wolseley Road #1 Pty Limited <Adsaleum Family A/C> 1,910,000 1.06%
    Mr Peter James Hendry 1,815,000 1.00%
    Morgan Stanley Australia Securities (Nominee) Pty Limited <No 1 Account> 1,465,998 0.81%
    Mr Philip John Cawood 1,420,179 0.78%
    Mr Jonathan James Kent 1,290,000 0.71%
    Finclear Services Pty Ltd <Superhero Securities A/C> 1,266,975 0.70%
    Ssra Pty Limited <Scully Family A/C> 1,241,000 0.69%
    Katilan Pty Ltd <Toby Investment A/C> 1,223,982 0.68%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 1,213,227 0.67%
    Danny Zanardo 1,122,135 0.62%
    Mr Peter Wade <Wade Family A/C> 1,034,081 0.57%
    Jadwat Pty Ltd <Jadwat Family S/F A/C> 1,032,500 0.57%
    Ltr Consulting Pty Ltd 982,143 0.54%
    Tempest Dawn Pty Limited <Swt Super Fund A/C> 976,087 0.55%

    Profile

    since

    Note